Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.67 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.67 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.67 |
| ▸ | NAMPT | P43490 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083467 | 0.88 | TRPV1 (0.75) | TRPV1NAMPTNPC1RAB9ALMNA | |
| SCHEMBL14083944 | 0.87 | CYP11B2 (0.58) | TRPV1CYP11B2CYP11B1NAMPTNPC1 | |
| SCHEMBL14083470 | 0.87 | TRPV1 (0.77) | TRPV1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14083509 | 0.86 | TRPV1 (0.69) | TRPV1NPC1RAB9AKDM4E | |
| SCHEMBL14082841 | 0.84 | TRPV1 (0.77) | TRPV1NAMPTMAPK1KMT2A | |
| SCHEMBL14083475 | 0.84 | TRPV1 (0.65) | TRPV1NPC1RAB9AMEN1MAPT | |
| SCHEMBL14083879 | 0.82 | TRPV1 (0.78) | TRPV1 | |
| SCHEMBL14083469 | 0.82 | TRPV1 (0.78) | TRPV1 | |
| SCHEMBL14082844 | 0.82 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL3872091 | 0.82 | TRPV1 (0.78) | TRPV1NAMPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885CYP11B2 2314/4885CYP11B1 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.